Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004075 · ClinicalTrials.gov registry record · Phase 1
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004075: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00004075 is a Phase 1 study that has completed, run by Mayo Clinic. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004075, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot be removed by surgery.
Interventions
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
What the finished NCT00004075 record still lists
NCT00004075 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which tanespimycin is the first listed.
NCT00004075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004075 about?
NCT00004075 is a clinical study titled "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot be removed by...
What is the current status of trial NCT00004075?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00004075?
The interventions under investigation include: tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00004075?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia